What Nefopam misr treats: Main Uses and Benefits

Nefopam misr is used to provide supportive relief for symptoms related to physical discomfort, and is relevant in contexts involving acute or disruptive symptom patterns.

This medication is commonly used for managing symptomatic relief in conditions presenting with acute episodes, such as severe post-operative pain, acute traumatic pain, dental pain, and ongoing musculoskeletal pain associated with conditions like rheumatoid arthritis and osteoarthritis.

“It is applied across domains where additional symptomatic support is needed, particularly when pain intensity is moderate to severe.”

This treatment is also applicable in clinical settings that involve acute or unstable symptom patterns, such as its inclusion in multimodal analgesia plans. This strategy may assist with reducing the patient’s reliance on opioid pain relievers, and supports improved comfort during periods of heightened symptoms.

---

Quick Fact: Used for Managing Moderate to Severe Pain

---

Nefopam misr is officially permitted for use by adults under standard labeled conditions. Eligibility is strictly defined by regulatory documents, which list specific patient groups and conditions for whom the medicine is either absolutely contraindicated or recommended for conditional use only.

The medication must not be used by patients with a history of convulsive disorders (epilepsy), a known hypersensitivity to the active substance, or those concurrently taking Monoamine Oxidase Inhibitors (MAOIs). It is also formally contraindicated for use in the treatment of myocardial infarction (heart attack).

Population Group	Regulatory Eligibility Status
Children Under 12 Years	Use not established; officially not recommended.
Pregnancy	Avoided; safety in human pregnancy is not established.
Breastfeeding	Must be discontinued due to risk of adverse effects in the infant.
Elderly Patients	Requires caution; a reduced starting dose is often recommended.
Renal/Hepatic Impairment	Requires caution; dose reduction is recommended for end-stage renal disease.

Use requires caution in patients with or at risk of angle closure glaucoma and urinary retention.

Interactions with other medicines and products

The interaction profile for Nefopam misr is formally documented by regulatory authorities, defining specific prohibitions and constraints with other medicinal products and substances. This information is derived strictly from official label text, establishing mandatory interaction requirements.

Contraindicated and High-Risk Combinations

The absolute prohibition for co-administration involves Monoamine Oxidase Inhibitors (MAOIs). This combination is officially contraindicated due to the severe, documented risk of hypertension and Serotonin Toxicity/Syndrome.

Significant pharmacodynamic augmentation is documented with several classes of agents:

• Serotonergic Agents: Medicines that increase serotonin availability (e.g., Tricyclic Antidepressants, SSRIs) carry an increased risk of Serotonin Toxicity/Syndrome.
• Anticholinergics: Risk of additive side effects (e.g., dry mouth, urinary retention) when co-administered with agents possessing anticholinergic activity.
• Sympathomimetics: Risk of additive side effects when co-administered with agents possessing sympathomimetic activity.

Other Documented Interaction Constraints

The medicine is officially noted to cause false positive results on screening tests for both benzodiazepines and opioids, a key procedural interference constraint. Furthermore, the label notes a drug-substance interaction with alcohol (ethanol), which may enhance central nervous system effects, increasing drowsiness. Population constraints also exist: hepatic or renal insufficiency is documented to interfere with the drug's metabolism and excretion, a factor recognized for potential accumulation.

How Nefopam misr works

Nefopam’s pharmacodynamic action involves a dual influence on central nervous system signaling pathways. Its primary mechanism is the inhibition of the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). By blocking the reuptake of serotonin and norepinephrine into the presynaptic neuron, the drug increases the effective concentration of these monoamines in the synaptic cleft

. This activity enhances transmission within the descending inhibitory pathways, which function to modulate the flow of signals in the spinal cord and brain.

Simultaneously, the drug acts as an antagonist at N-Methyl-D-Aspartate (NMDA) receptors, key sites for excitatory signaling mediated by glutamate. By partially obstructing the ion channel associated with the NMDA receptor, Nefopam limits the ion conductance that underlies the sustained firing and sensitization of nerve cells. The combined effect of enhanced central inhibition and reduced neuronal excitability results in an overall alteration of signal processing dynamics, leading to a physiological shift toward reduced signal output within the system.

Official Administration Guidelines

Nefopam is provided in two main formats: an oral form (tablets) and a sterile injectable solution, which governs its official routes of administration and usage context.

Route	Standard Adult Dosing (Per Dose)	Frequency Pattern
Oral (Tablets)	30 mg to 90 mg (maximum 270 mg/day)	Three times daily (TDS)
Parenteral (IM/IV)	20 mg (maximum 120 mg/day)	Every 4 to 6 hours, as needed

---

Administration Method and Timing

For oral use, the standard recommended starting dosage is often 60 mg (two 30 mg tablets), taken three times a day. The tablets can be taken with or without food and should be swallowed whole. The usual total oral daily intake must not exceed 270 mg.

For the injectable solution, administration is restricted to the deep intramuscular (IM) route or via a slow intravenous (IV) infusion. Intravenous administration must be conducted over a period longer than 15 minutes; the solution may be diluted with standard solutions like isotonic sodium chloride.

Population-Specific Dosing Rules

Official prescribing information mandates high-level dose adjustments for sensitive patient groups:

• Older Adults: A reduced starting dose is strongly recommended, typically 30 mg three times daily, due to slower metabolism.
• Renal Impairment: Patients with end-stage renal disease require a reduced daily dose to avoid increased serum concentrations of the medicine.
• Pediatric Use: Nefopam is generally not recommended for administration to children under 12 years of age.

These instructions define the standardized, label-based approach for the correct clinical use of the medicine, dictating the route, dose limits, frequency, and necessary adjustments.

Nefopam misr: Recent Clinical Evidence

Nefopam is a non-opioid, centrally-acting analgesic widely studied for its role in multimodal analgesia, primarily in acute pain management settings. Its distinct action—inhibiting the reuptake of neurotransmitters like serotonin, norepinephrine, and dopamine—is thought to modulate pain signals in the central nervous system.

---

Efficacy and Opioid-Sparing Effects

Recent meta-analyses and systematic reviews have primarily explored the use of Nefopam in postoperative pain management, often comparing it to placebo or other common analgesics.

• Opioid Reduction: Studies consistently show that the use of Nefopam is associated with a significant reduction in total postoperative opioid consumption (e.g., morphine or fentanyl) compared to placebo. This is often referred to as an opioid-sparing effect.
• Pain Intensity: Findings regarding Nefopam's direct effect on reducing pain intensity scores (such as VAS or NRS) have been mixed. Some reviews indicate that, when used alone, Nefopam may not cause a statistically significant difference in pain severity at very early time points (e.g., 30 or 60 minutes post-surgery) compared to placebo, while other analyses support a reduction in pain levels.
• Rescue Analgesia: Nefopam administration has been shown to lengthen the time to the first request for rescue analgesia, suggesting a delay in the onset of pain requiring intervention.

---

Tolerability and Adverse Events

In the studied populations, Nefopam is generally considered to have a distinguishable side effect profile from opioids and Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Adverse events reported in clinical trials frequently include:

• Nausea and Vomiting
• Sweating (Diaphoresis)
• Tachycardia (increased heart rate)

These effects are typically dose-dependent. The lack of respiratory depression makes it a preferred non-opioid component in some multimodal pain protocols, but the potential for anticholinergic and sympathomimetic effects requires careful consideration, especially in older adults or those with pre-existing cardiac conditions.

Common questions about Nefopam misr (FAQ)

Q: What class of drug does Nefopam misr belong to?

A: According to official documentation, Nefopam misr is classified as a centrally-acting non-opioid analgesic. The classification indicates that it is understood to work primarily in the central nervous system to relieve pain without binding to opioid receptors, unlike narcotic medications. The unique chemical class the medicine belongs to is the benzoxazocine derivative group.

Q: How does the action of Nefopam misr differ from common painkillers like ibuprofen or paracetamol?

A: The official product information notes that Nefopam misr has no anti-inflammatory or fever-reducing (antipyretic) action. This difference is significant when compared to Non-Steroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen. The medicine works by altering pain signals in the central nervous system, not by reducing local inflammation.

Q: Does Nefopam misr help with inflammation?

A: Official pharmacological information specifically states that Nefopam misr has no anti-inflammatory action. Its established role is that of an analgesic, meaning it works to relieve pain, but it does not treat or reduce inflammation in the body.

Q: How quickly does Nefopam misr start working after the first dose?

A: Following an intramuscular (IM) injection, studies indicate that the maximum concentration of the medicine in the blood is typically reached within 30 to 60 minutes after the dose. This timeframe relates to when the highest concentration of the medicine is typically measured in the bloodstream.

Q: How long does the pain-relieving effect of Nefopam misr typically last?

A: The average serum half-life of the medicine is approximately 5 hours after intramuscular administration. The half-life refers to the time required for half the drug to be eliminated from the body, and this average time is a factor considered by prescribers in establishing dosing intervals.

Q: Is Nefopam misr primarily used for acute pain, chronic pain, or both?

A: Official marketing authorization and regulatory guidance restrict the medicine's prescription to the management of acute pain. Official guidance indicates that treatment duration is generally short, and its use for long-term chronic pain management is considered a non-recommended use based on the current authorization.

Q: What is the typical timeframe for reviewing Nefopam misr treatment, according to medical guidance?

A: Based on the official marketing authorization, treatment with this medicine is typically restricted to the management of acute pain. For this reason, official guidance suggests that the medicine should generally be used only for a short duration.

Q: Is there a reported risk of becoming addicted to or dependent on Nefopam misr with long-term use?

A: Although Nefopam is officially classified as a non-opioid, reports in medical literature suggest that a potential risk exists, particularly when the drug is used for chronic pain or for prolonged periods.

Q: Are hallucinations or confusion listed as possible side effects of Nefopam misr?

A: Yes, confusion and hallucinations are listed as documented adverse effects in official summaries of product characteristics. Official product information notes that older adults may be more susceptible to these central nervous system (CNS) effects.

Q: Can Nefopam misr affect the heart rate?

A: The side effect profile lists tachycardia (an increased heart rate) and palpitations as common or uncommon adverse reactions. Such effects are understood to be related to the medicine's action on the central nervous system.

Q: Can Nefopam misr cause confusion?

A: Confusional states are officially listed as a documented adverse effect of the medicine. This is a central nervous system effect that is noted in official documentation, especially concerning older patients.

Q: Can Nefopam misr affect a person's blood pressure?

A: The medicine is associated with a few effects on blood pressure. Side effect information lists hypotension (low blood pressure) as a possible adverse reaction, and some transient increases in blood pressure have also been observed.

Q: Does Nefopam misr affect the ability to drive or operate machinery?

A: The medicine can cause side effects like dizziness, light-headedness, and confusion, which may impair the ability to perform skilled tasks. Caution is generally advised due to the potential for these side effects to impair the ability to perform skilled tasks.

Q: What non-prescription medicines should be used with caution alongside Nefopam misr?

A: Non-prescription medicines that cause sleepiness, a dry mouth, or difficulty urinating should be used with caution because Nefopam misr may make these effects worse.

Q: Are there concerns about taking Nefopam misr with over-the-counter medicines like sedating antihistamines?

A: Caution is advised when taken with any medicines that possess anticholinergic activity, which includes some sedating antihistamines. The combination may carry a potential for increased side effects, such as dry mouth or difficulty urinating.

Q: Does Nefopam misr interact with cough suppressants?

A: Cough suppressants that possess anticholinergic activity carry a potential for additive side effects and should be used with caution.

Q: What specific eye conditions (like glaucoma) are a concern when taking Nefopam misr?

A: The medicine is officially contraindicated (must not be used) in people known to be at risk of angle-closure glaucoma (a specific form of the condition).

Q: Are there any specific concerns about Nefopam misr use for patients with prostate issues?

A: The medicine is officially contraindicated (must not be used) in patients who have a risk of urinary retention due to urethroprostatic disorders, which includes certain prostate conditions.

Q: What is the concern about Nefopam misr and seizures?

A: The medicine is officially contraindicated (must not be used) for patients with a history of convulsive disorders. Regulatory sources document that seizures and status epilepticus are serious, unpredictable adverse reactions associated with the medicine.

Q: What information is available on the risk of overdose with Nefopam misr?

A: Overdose is a serious risk characterized by neurological effects, such as seizures and agitation, and cardiovascular effects, including coma and tachycardia (increased heart rate). The risk of serotonin toxicity is also noted if taken alongside other serotonergic drugs.

Q: Does Nefopam misr help with pain from nerve issues?

A: Research has investigated the medicine's potential role in treating neuropathic pain (nerve-related pain). This interest is due to its mechanism of action, which involves modulating neurotransmitter activity and blocking NMDA receptors, similar to other drugs used for nerve pain.

Q: Is it true that Nefopam misr is sometimes used for shivering?

A: Medical literature and historical use note that the medicine is documented as effective for the prevention of shivering that may occur during or after surgical procedures.

Q: What is the information available on the effectiveness of Nefopam misr for chronic non-cancer pain?

A: The official marketing authorization (AMM) for the drug specifies that prescription should be restricted to the management of acute pain. Research evidence and guidelines mainly focus on its use in the short-term, acute setting.

Q: What should be known about taking Nefopam misr with herbal supplements?

A: Caution is advised with herbal supplements that may cause sleepiness, a dry mouth, or difficulty urinating. These supplements should be used carefully as Nefopam misr may make these specific side effects worse.

Official Storage and Disposal Requirements

The storage and disposal of Nefopam misr (Nefopam Hydrochloride) must comply strictly with conditions specified in the official regulatory labeling.

Storage Condition	Requirement
Temperature	Store below 30 C or 25 C, depending on the specific product formulation.
Child Safety	Must be kept out of the sight and reach of children to prevent accidental ingestion.
Stability	The medicine must not be used after the expiry date (EXP) printed on the packaging.
Handling	Some formulations, particularly the injection solution, require storage protected from light.

For disposal, the product must not be thrown away via household waste or wastewater. To ensure proper environmental protection, patients are instructed to ask a pharmacist how to dispose of unused or expired medicine.